Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Add To Watchlist

Bullboard (TSXV:ARCH)

View:

Post by TechTitanon Apr 12, 2023 11:07pm

Copy and Paste King Riverfolk

The same old copy and paste post crack me up! What are you trying to gain from this?

169

Post by Riverfolkon Apr 08, 2023 9:18pm

LSALT / Metablok Preclinical

Arch scientists have demonstrated Metablok’s ability to block the inflammatory response triggered in the lung and liver with lipopolysaccharide (LPS) induced inflammation and in the kidney ...more

198

Post by Riverfolkon Apr 08, 2023 9:17pm

LSALT / Metablok Background

Inflammation Based Disease Inflammation is a localized physical condition that involves the activation of the immune system in response to infection, tissue injury, or autoimmunity. Inflammation is ...more

198

Post by Riverfolkon Apr 08, 2023 9:10pm

dipeptidase-1 contribute to contrast-induced AKI

Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury https://www.ncbi.nlm.nih.gov

122

Post by Riverfolkon Apr 08, 2023 9:07pm

LSALT Peptide (Metablok) team – lead scientists

LSALT Peptide Team

128

Post by Riverfolkon Apr 08, 2023 9:04pm

Dipeptidase-1 governs renal inflammation

Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury https://www.science.org

130

Post by Riverfolkon Apr 08, 2023 9:00pm

Dipeptidase-1 - Adhesion Receptor for Neutrophil Recruitor

Dipeptidase-1 Is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver https://www.cell.com

127

Post by Riverfolkon Apr 08, 2023 8:56pm

Prime Minister Trudeau on Arch Biopartners

PM Trudeau 6.7 Mil Announcement

158

Post by Riverfolkon Apr 08, 2023 8:54pm

LSALT / Metablok Human Trials

clinicaltrials.gov

Post by Riverfolkon Apr 08, 2023 8:49pm

About DPEP-1 and Organ Inflammation

A scientific team led by Arch scientists Dr. Donna Senger and Dr. Stephen Robbins first described a novel mechanism of action for organ inflammation in the journal Cell in August 2019. In ...more

149

Post by Riverfolkon Apr 08, 2023 8:44pm

(CIHR) Project Grant worth $1,109,250

To further study the role of dipeptidase-1 (DPEP-1) in renal inflammation and chronic kidney disease (CKD). The CIHR grant entitled “A Multifaceted Function for Dipeptidase-1 in Kidney Injury” was ...more

161

Post by Riverfolkon Apr 08, 2023 8:41pm

ARCH $4,000,000 funding from the National Research Council

The research and development funding from NRC IRAP will help support several sub-tasks needed to advance the LSALT peptide drug program. These include: dose escalation studies; costs ...more

116

Post by Riverfolkon Apr 08, 2023 8:34pm

Active Pharma Executive - ARCH Strategic Advisor

Mr. Farris Smith started his career with AP Moller in 2001 and joined Novo Nordisk in 2003 as head of Finance and Human Resources for the Arabian Gulf countries and has since held finance and ...more